# Skeletal Fragility

> **NIH NIH P01** · MAYO CLINIC ROCHESTER · 2020 · $558,266

## Abstract

PROJECT 2: The Role of Cellular Senescence in Skeletal Aging – SUMMARY Khosla/Farr
Project 2, “The Role of Cellular Senescence in Skeletal Aging,” tests the hypothesis that targeting senescent
cells using senotherapeutic compounds can delay, prevent, or alleviate age-related bone fragility. Although our
published and additional preliminary data strongly support this hypothesis, a better understanding of the
mechanisms responsible for age-related skeletal dysfunction is needed to guide development and translation
of senotherapeutics for osteoporosis. In this Project, we address several key, unresolved questions regarding
the role of cellular senescence in mediating age-related bone loss: (1) What are the mechanisms of p16Ink4a- vs
p21Cip1-driven senescence as well as that of specific senescent cell types in the bone microenvironment in
causing age-related bone loss?; (2) Does clearance of senescent cells enhance the skeletal response to an
anabolic stimulus?; and (3) Do senescent cells modulate fracture healing? In addition to these Project-specific
questions, we will derive skeletal tissues from the common animal models in Core C (Healthspan Phenotyping)
to test novel senotherapeutics from Core B (Drug Discovery & Development) for skeletal efficacy and to extend
findings in mice to rats using a novel transgenic rat model (INK-ATTAC rat). We will address these questions in
the context of our 3 Specific Aims: Aim 1. Define the mechanisms by which senescent cells cause age-
related bone loss and marrow adiposity. Using a newly developed p21-ATTAC mouse and novel transgenic
mouse, LOX-ATTAC, capable of cellular- and temporal-specific senescent cell clearance, we will test the
relative contributions of (Aim 1a) p16Ink4a- vs p21Cip1-driven senescence and (Aim 1b) specific cell types in
bone (myeloid cells, osteoprogenitors, osteocytes) in mediating age-related skeletal fragility and marrow fat
accumulation. In Aim 1c, we will define how the SASP simultaneously inhibits bone formation and stimulates
marrow adipogenesis; then, we will identify the most important SASP factors responsible using neutralizing
antibodies and pharmacological approaches. Aim 2. Evaluate the impact of senescent cell clearance on
anabolic skeletal therapies and fracture healing. In Aim 2a, we will determine whether clearance of senescent
cells enhances the skeletal response to anabolic stimuli [intermittent PTH (1-34) and sclerostin antibody
therapy]. In Aim 2b, we will test whether clearance of senescent cells impairs fracture healing in young mice
but enhances fracture healing in aged mice. Aim 3. Identify and optimize interventions that alleviate
senescence-related skeletal fragility in two species. In Aim 3a, we will evaluate the senotherapeutic
compounds developed in Core B for skeletal efficacy using the common mouse models described in Core C. In
Aim 3b, we will use the INK-ATTAC rat model common to all Projects to test whether clearing senescent cells
also prevents age-re...

## Key facts

- **NIH application ID:** 9938402
- **Project number:** 5P01AG062413-02
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** Sundeep Khosla
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $558,266
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9938402

## Citation

> US National Institutes of Health, RePORTER application 9938402, Skeletal Fragility (5P01AG062413-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9938402. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*